Arch Venture Partners, fresh from co-founding the massively financed Seattle biotech startup Juno Therapeutics, has closed on a new venture capital fund topping $400 million.

The company, with offices in Chicago, Seattle, Austin and San Francisco, focuses on seed and early-stage technology. Its local partner, Robert Nelsen, said “Seattle will figure prominently in our plans” for investing the money, likely in 20 to 25 companies.

While Arch will “continue to do things all over the place,” Seattle-area academic and nonprofit institutions provide “a strong research base” for new startups, particularly in life sciences sectors such as genomics, immuno-oncology, neurology and global health, he said.